GenEdit
Manufacturing · California, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
681 Gateway Blvd Fl 3, South San Francis...Phone Number
(510) 574-5475Website
www.genedit.comRevenue
$8.2 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
3
2
1
1
1
1
About GenEdit
At GenEdit, the company's mission is to discover and develop innovative genetic medicines with targeted in vivo delivery. The company's NanoGalaxy platform of non-viral, non-lipid polymer nanoparticles will enable a universe of opportunities to launch the next generation of safe and effective genetic medicines. To bring these medicines to patients, the company is developing the company's own internal pipeline and delivering a wide variety of therapeutic payloads for the company's partners' programs.Explore more
GenEdit Org Chart
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is GenEdit your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Product Launch: Get notified when GenEdit launches new products
Earning: See what the market has to say on GenEdit recently announced quarterly report
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Website visits: Recent activity has been detected on your website
Congratulate Masked Content for being promoted to Masked Content at GenEdit
Click to see if GenEdit had a recent Job posting/layoffs
Check out if GenEdit is spiking on competitors!
GenEdit, which may be a good buyer, showed buying intent in Masked Content Topic
Check if GenEdit has recently received funding, and reach out quickly before it becomes old news!
Funding: Get notified immidiatlly once GenEdit has new funding data
Recommended Actions
Reach out to Masked Content who joined GenEdit as Masked Content
Find more new buyers
Compare Similar Companies to GenEdit
Compare insights from companies similar to GenEdit, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
GenEdit is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
GenEdit is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about GenEdit.
GenEdit financials insights
Gather financial insights about GenEdit, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2018
Angel/Seed
$8.5M
2021
Series A
$26M
2024
Other Financing Round
$24M
2026
Series B
$60M
GenEdit Tech Stack
A closer look at the technologies used by GenEdit
Most Recent Scoops
Funding
Funding
Event
Product Marketing, Events, Learning & Development, Software, Bioengineering, Pharmaceuticals, Public Health, Field /Outside Sales, Field Marketing, Healthcare Technology, Patient Experience
Award
Award, Search, Medical Research, Business Finance, Clinical Operations, Finance, Operations
New Hire
Executive Move
Executive Moves, New Hire
Open Position
GenEdit News & Media
BreezeBio banks $60M to make more precise genetic medicines - BioPharma Dive
The company has shed its former “GenEdit” name and strategy in favor of a plan to develop its own medicines, starting with a potential tolerance-inducing treatment for Type 1 diabetes.GenEdit Appoints Dr. J. Rodrigo Mora as Chief Scientific Officer to Expand Its NanoGalaxy® Genetic Medicine Platform into Immunology
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- #CRISPR--GenEdit Appoints Dr. J. Rodrigo Mora as Chief Scientific Officer to Expand Its NanoGalaxy® Genetic Medicine Platform into ImmunologyGenEdit raises $24M, signs Genentech deal - C&EN - American Chemical Society
The firm’s polymer nanoparticles will be used to target autoimmune disorders.GenEdit Announces Multiyear Collaboration and License Agreement with Genentech to Develop Novel Nanoparticles to Deliver Genetic Medicines for Autoimmune Disease
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- #CRISPR--GenEdit Announces Multiyear Collaboration and License Agreement with Genentech
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding GenEdit
Sign Up For FreeTo access detailed company insights
At GenEdit, the company's mission is to discover and develop innovative genetic medicines with targeted in vivo delivery. The company's NanoGalaxy platform of non-viral, non-lipid polymer nanoparticles will enable a universe of opportunities to launch the next generation of safe and effective genetic medicines. To bring these medicines to patients,... Read More
